Pashtoon Kasi, Medical Director of GI Medical Oncology at City of Hope Orange County, shared on X:
“Unveiling FULL results of our NEST Trial in MSS ‘cold’ colorectal cancer.
Immunotherapy (BOT/BAL) BEFORE surgery.
- 100% disease-free to date
- NEST1:~32 months
- NEST2:~24 months
5 years of work – now in Clinical Cancer Research.
NEST3 NOW OPEN!”
Title: Neoadjuvant Botensilimab/Balstilimab for localized mismatch repair proficient and deficient colon cancer: Results of the NEST phase 2 clinical trial
Authors: Manish A. Shah, Erika Hissong, Mehraneh D. Jafari, Pashtoon Murtaza Kasi, Maider Astorkia, Sahrish Khan, Casey Owens, Zhengming Chen, Heather Yeo, Fabio Socciarelli, Sandipto Sarkar, Alana Nguyen, Despina Siolas, Allyson Ocean, Kelly Garrett, Lea Lowenfeld, Alessio Pigazzi, Preethi Guniganti, Sanjay Patel, Doron Betel, Manuel Hidalgo
Read The Full Article
You may also be interested in: Inside the ROBBIN Phase 3 Strategy: Bringing BOT+BAL Into the Neoadjuvant Setting
